Loyola University Chicago

Loyola eCommons
Master's Theses

Theses and Dissertations

2017

Multifunctional Regulatory T Cells from Human Umbilical Cord
Blood and the Role of Tumor Necrosis Factor in Immune
Homeostasis
Alexander Nelson
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_theses
Part of the Immunology and Infectious Disease Commons

Recommended Citation
Nelson, Alexander, "Multifunctional Regulatory T Cells from Human Umbilical Cord Blood and the Role of
Tumor Necrosis Factor in Immune Homeostasis" (2017). Master's Theses. 3695.
https://ecommons.luc.edu/luc_theses/3695

This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It
has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 2017 Alexander Nelson

LOYOLA UNIVERSITY CHICAGO

MULTIFUNCTIONAL REGULATORY T CELLS FROM HUMAN UMBILICAL CORD
BLOOD AND THE ROLE OF TUMOR NECROSIS FACTOR IN IMMUNE HOMEOSTASIS

A THESIS SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDACY FOR THE DEGREE OF
MASTER OF SCIENCE

PROGRAM IN INFECTIOUS DISEASE AND IMMUNOLOGY

BY
ALEXANDER J NELSON
CHICAGO, ILLINOIS
AUGUST, 2017

Copyright by Alexander J Nelson, 2017
All rights reserved.

TABLE OF CONTENTS
LIST OF FIGURES

v

ABSTRACT

vi

CHAPTER ONE: INTRODUCTION
Immune Tolerance
Regulatory T Cells
Foxp3
Mechanisms of suppression
Regulatory T cell subsets
Chemokine Receptors and T Cell Trafficking
Fetal Tolerance and Neonatal Immunity
Tumor Necrosis Factor Biology
TNF signaling
TNF in human disease

1
2
3
5
6
8
9
11
12
12

CHAPTER TWO: MATERIALS AND METHODS
Mononuclear Cell Isolation and Cell Purification
Treg Induction
Antibodies
Flow Cytometry
Suppression Assay
Survival Assay
Statistical Analysis

14
14
15
15
15
16
16

CHAPTER THREE: PROPENSITY FOR TREG DIFFERENTIATION BY NAÏVE T CELLS
FROM HUMAN UMBILICAL CORD BLOOD
Introduction
17
The Role of TCR Signaling in Treg Generation
18
Plasticity of Cord Blood Naïve T Cells in Response to Polarizing Cytokines
20
Discussion
23
CHAPTER FOUR: PHENOTYPE OF CORD BLOOD TREGS IN COMPARISON TO ADULT
PERIPHERAL BLOOD TREGS
Introduction
26
Cord Blood Tregs Express Chemokine Receptors and are Distinct from Adult tTregs
27
Cord Blood Tregs Express Distinct Surface Antigens
28
Cord Blood Tregs Express Distinct Cytokine Profile
31
Discussion
34
Chemokine receptor expression
34
Surface antigen phenotype
35
Cytokine profile
37
iii

CHAPTER FIVE: FUNCTION OF TUMOR NECROSIS FACTOR SIGNALING IN TREGS
Introduction
41
Effect of TNF on Treg Differentiation
41
Effect of TNF on Suppressive Activity of Tregs
43
Adult Foxp3+ Tregs Express Membrane TNF
44
Function of Treg-derived TNF
48
Discussion
51
CHAPTER SIX: GENERAL DISCUSSION

54

REFERENCE LIST

58

VITA

76

iv

LIST OF FIGURES
Figure 1. Decreasing anti-CD3 stimulation reduces Foxp3 expression

19

Figure 2. Effect of anti-CD3 concentration on T cell proliferation

20

Figure 3. Treg differentiation in response to Th17 and Th1 polarizing cytokines

22

Figure 4. Chemokine receptor expression by cord blood and adult Tregs

28

Figure 5. Surface antigen expression by cord blood and adult Tregs

30

Figure 6. Distinct cytokine profile of cord blood Tregs

32

Figure 7. Effect of TNF inhibition on cord blood Treg generation

42

Figure 8. Effect of TNF inhibition on suppressive activity of cord blood and adult Tregs

44

Figure 9. Expression of TNF by human Foxp3+ Tregs

46

Figure 10. Treg survival in response to TNF inhibition

50

Figure 11. Effect of TNF neutralization on apoptosis and cell proliferation

51

v

ABSTRACT
Regulatory T cells (Tregs) are required to suppress inflammation and prevent
autoimmunity. During fetal development Tregs are crucial to maintain tolerance between mother
and child. After birth, neonates require tolerance to avoid harmful immune responses to foreign
antigens in food and allow colonization with commensal microbes. We demonstrate a propensity
for T cells in human umbilical cord blood to differentiate into Tregs in response to antigen
receptor stimulation ex vivo. Cord blood-derived Tregs potently suppress T cell proliferation,
but also produce pro-inflammatory cytokines known to activate innate immune responses. These
results suggest that antigen exposure during early life results in development of T cells with both
regulatory and effector functions. Surprisingly, we observe expression of tumor necrosis factor
(TNF) by cord blood and adult Tregs. We show a role for autocrine TNF signaling in survival of
Tregs, suggesting an important function for TNF in immune tolerance and homeostasis.
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CHAPTER ONE
INTRODUCTION
Immune Tolerance
The concept of immune tolerance was first demonstrated in 1945 by Ray Owen, who
observed that dizygotic twin cattle shared red blood cells in the placenta which persisted into
adult life1. The absence of immune response to the foreign red blood cells in the blood of cattle
suggested that immune tolerance could be generated in response to foreign cells acquired before
birth. In 1953 Billingham, Brent, and Medawar demonstrated that mice inoculated in utero with
cells from a different strain of mouse were tolerant to skin grafts from the same strain in adult
life2. Importantly, this study found that induction of tolerance for foreign tissues was dependent
on the timing of exposure. Mice that were injected with foreign cells after birth demonstrated a
lack of tolerance to skin grafts, suggesting that the developing immune system was somehow
biased toward the acquisition of tolerance. These studies laid the groundwork for the concept of
acquired immunological tolerance, for which Burnet and Medawar won the 1960 Nobel Prize in
Physiology or Medicine3. In 1961, Miller discovered the role of the thymus in generation of
immune tolerance4, which led Burnet to hypothesize that immune tolerance was maintained via
the elimination of self-reactive lymphocytes3.
In the late 1980s, Marrack and colleagues demonstrated that tolerance to self-antigens
was the result of removal of autoreactive T cells during thymic selection, a process now called
clonal deletion5. Removal of autoreactive T cells in the thymus is now known to be mediated by
1
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the transcription factor AIRE, or autoimmune regulator, which is expressed in the thymus6.
AIRE drives medullary thymic epithelial cells (mTECs) to express self-antigens from peripheral
tissues, resulting in apoptosis of T cells that bind to these proteins and thus preventing T cell
responses to self-antigens in the periphery7.
A second mechanism for immune tolerance was described by Nossal, who discovered the
presence of mature, autoreactive B lymphocytes in circulation which failed to respond to antigen
stimulation8. Clonal anergy, as this new mechanism came to be called, was similarly described
in T cells by Jenkins and Schwartz, who observed that the absence of costimulatory signals
during antigen stimulation resulted in unresponsiveness upon subsequent stimulation9. These
studies demonstrate anergy as another means by which tolerance can be maintained during
thymocyte development in the thymus.
Clonal deletion and anergy maintain tolerance by preventing peripheral immune
responses by autoreactive lymphocytes. However, until 1970 an active mechanism for peripheral
tolerance had not been identified10. Gershon and Kondo discovered that T cells were able to
suppress immune responses in addition to mediating them, identifying a distinct population of T
cells initially referred to as suppressor T cells11. However, due to difficulty in definitive
identification of this new cell population and a lack of evidence of their role in disease, studies of
suppressor T cells waned during the 1980s10. Despite this, however, studies of autoimmune
disease revealed a population of T cells that were responsible for maintenance of self-tolerance12.
Regulatory T Cells
Beginning in 1969, a series of experiments revealed a population of T cells that inhibited
the development and progression of autoimmune disease in mice and rats10. Nishizuka and
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Sakakura demonstrated that thymectomized neonatal mice developed autoimmune destruction of
ovaries13. Further, other groups showed that thymectomy of adult rats in conjunction with
radiation resulted in autoimmune thyroiditis and type 1 diabetes14, 15. Importantly, syngeneic
transfer of T cells, in particular CD4+ T cells, from normal animals abrogated disease15. These
studies provided evidence for the hypothesis that the thymus produces CD4+ T cells with the
ability to suppress T-cell mediated autoimmune disease, prompting investigations aimed at
determining a way to identify these suppressive T cells10. In 1995, Sakaguchi et al. discovered
that the suppressive population of CD4+ T cells expressed the IL-2 receptor CD2516. Depletion
of CD4+CD25+ T cells resulted in the development of organ-specific autoimmune disease and
reconstitution of this group of cells prevented the onset of symptoms, suggesting that expression
of CD25 could be used to identify suppressive T cells16-18. Furthermore, several studies
demonstrated the functional importance of CD25 expression as a receptor for IL-2. IL-2deficient mice developed autoimmunity and exhibited a paucity of CD4+CD25+ cells while
maintaining a normal composition and number of T cells19. IL-2 was also identified as a growth
factor for CD4+CD25+ suppressive T cells, as antibody-mediated neutralization of endogenous
IL-2 reduced CD4+CD25+ T cell numbers and resulted in onset of autoimmune disease20.
Foxp3.
Identification of the transcription factor forkhead box P3, or Foxp3, in 2001 provided a
crucial phenotypic and functional marker for regulatory T cells (Tregs), as they came to be
called21. The discovery came from investigations into the cause of the fatal lymphoproliferative
disorder of scurfy mice, and identified a single gene mutation in the X-chromosome responsible
for a loss of Foxp3 expression22. Subsequently, a mutation in Foxp3 was also identified as the
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cause of the human disease IPEX (immune dysregulation, polyendocrinopathy, enterophathy, Xlinked syndrome), a fatal disease characterized by excessive inflammation and multi-system
autoimmunity23. The symptoms observed in scurfy mice and IPEX patients closely resembled
those of mice deficient in CD4+CD25+ T cells, giving rise to the hypothesis that mutations in
Foxp3 depleted Tregs and resulted in excessive lymphoproliferation and inflammation24. By
2003, several studies supported the role of Foxp3 in generation and suppressive function of
Tregs. Foxp3 expression was confirmed in CD4+CD25+ T cells with suppressive function, and
retroviral transduction of Foxp3 induced suppressive function and Treg phenotype in naïve T
cells25. Furthermore, experiments in mice demonstrated the requirement of Foxp3 in Treg
development, solidifying Foxp3 as the regulatory T cell lineage-specifying transcription factor26,
27

. While the precise function of Foxp3 in suppressive activity of Tregs remains poorly

understood, whole genome analyses in mice indicate Foxp3 acts as both a transcriptional
activator and repressor, acting in concert with other transcription factors to influence expression
of hundreds of genes28. Specifically, Foxp3 is known to form complexes with NFAT, repressing
expression of IL-2 and upregulating Treg surface markers CD25 and cytotoxic T-lymphocyteassociated antigen-4 (CTLA-4)29, 30. Interaction of Foxp3 with AML1 (acute myeloid leukemia
1 or Runx1) has also been tied to suppression of IL-2 and interferon-gamma production while
activating suppressive activity of Tregs and upregulating glucocorticoid-induced TNF-receptorfamily-related protein (GITR) 31. Importantly, while Foxp3 expression in mice is limited to
Tregs, human T cells transiently express low levels of Foxp3 during T cell receptor (TCR)
stimulation in contrast to stable expression in Tregs32.

5

Mechanisms of Suppression.
Despite extensive studies on the function of Tregs in vivo and in vitro, the mechanisms of
by which Tregs suppress effector T cell proliferation and inflammation remain poorly
understood. Furthermore, several studies suggest Tregs not only directly suppress T cell
responses, but also alter the activity of antigen-presenting cells (APCs) as an indirect means of
modulating immune responses33. To date, many mechanisms of Treg-mediated suppression have
been proposed, falling broadly into two classes: contact-dependent and contact-independent34.
Importantly, while Treg suppression requires antigen stimulation via TCR activation, activated
Tregs can suppress in an antigen-nonspecific manner referred to as bystander suppression33.
Therefore, Tregs can modulate immune responses by T cells independent of TCR specificity.
Initial investigations into Treg suppression revealed that in vivo CTLA-4 blockade resulted in
development of autoimmune disease in mice and abrogated in vitro suppression of T cell
proliferation35, 36. Subsequent studies revealed that CTLA-4 on Tregs inhibited T cell activation
by competitively binding B7 molecules on APCs, preventing costimulatory signal transduction
via CD28 on T cells37, 38. Thus, Tregs can prevent activation and proliferation of conventional T
cells in a contact-dependent manner. Direct cytotoxicity by Tregs has also been observed,
demonstrating that under some conditions Tregs are capable of killing a variety of target cells to
control immune responses by expression of granzyme A and perforin39. Production of cyclic
adenosine monophosphate (cAMP) by Tregs is implicated in contact-dependent suppression,
particularly in vitro35. A potent inhibitor of proliferation and IL-2 production, cAMP has been
shown to transport across cell membranes through gap junctions formed between Tregs and
conventional T cells40. Moreover, the suppressive activity of Tregs is abrogated in the presence
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of a cAMP antagonist as well as by the use of a gap junction inhibitor40. While in vitro studies
suggest contact-dependent mechanisms are the dominant form of Treg suppression, several
disease models implicate the production of immunosuppressive cytokines are important for Treg
function in vivo. Studies of inflammation in rodents demonstrate the requirement of interleukin
10 (IL-10) and transforming growth factor beta (TGF-β) production by Tregs in control of
immune pathology41, 42. Tregs produce both soluble and membrane-bound TGF-β, and notably
blockade of TGF-β in vitro mildly reduces suppression of both human and mouse T cell
proliferation43, 44. Control of intestinal inflammation also requires IL-10 and TGF-β production
by Tregs45. Taken together, these studies demonstrate the complex nature of Treg suppression.
Tregs employ a variety of mechanisms to maintain tolerance and downregulate inflammation,
and the exact manner of suppression is likely dependent on many factors including the type of
immune response, tissue site, and cell types involved. Furthermore, recent evidence reveals that
Tregs are not a homogeneous population, but rather a complex group of distinct subsets with
specific functions.
Regulatory T cell subsets.
The majority of Tregs are produced in the thymus (nTregs/tTregs), however Tregs can
also be generated in peripheral tissues (pTregs) and induced in vitro from naïve T cells
(iTregs)46. During development in the thymus, T cells reactive against self-antigens expressed
on mTECs are either deleted by apoptosis, become anergic, or become Foxp3+ Tregs, which
leave the thymus and enter peripheral tissues to maintain self-tolerance17, 47. Additionally,
mature, naïve T cells in the periphery can become Foxp3+ Tregs when stimulated with high
affinity cognate antigen in the presence of TGF-β and IL-248, 49. Similarly, naïve T cells can be
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induced to express Foxp3 and acquire suppressive function in cell culture by TCR stimulation in
the presence of TGF-β and IL-249. Recent studies in mice and humans elucidated a
heterogeneous population of CD8+CD25+Foxp3+ T cells with functional suppressive activity50,
51

. While the role of CD8+ Tregs in immune homeostasis remains unclear, patients with asthma

and inflammatory bowel disease display a paucity of CD8+ Tregs52, 53. Therefore, CD8+ Tregs
may play distinct roles in maintenance of immune homeostasis, perhaps preferentially
controlling specific types of immune responses. CD4+ T cells with suppressive activity in the
absence of Foxp3 expression have been identified in mice, including IL-10-producing Tr1 cells
and TGF-β-secreting Th3 cells54-56. However, the suppressive activity of Foxp3- Treg subsets is
limited to immunosuppressive cytokine secretion, and in the case of Th3 cells, driving peripheral
Foxp3+ Treg induction through the expression of TGF-β56. Due to the wide variety of immune
responses required to defend against pathogens, the diversity of Treg function and phenotype is
not surprising. Indeed, recent reports indicate that Foxp3+ Tregs exist in distinct populations
with precise anti-inflammatory roles57.
Naïve T cells differentiate into effector subsets based on TCR stimulation in the presence
of a specific cytokine environment and can be distinguished based on the cytokines and
transcription factors they express58. Interleukin 12 (IL-12) drives Th1 differentiation, resulting
in interferon-gamma (IFN-γ) production and expression of the transcription factor T-bet59-61.
Similarly, Th2 cells require interleukin 4 (IL-4) and express IL-4 and GATA-3, while Th17 cells
are induced by TGF-β and interleukin 6 (IL-6) and express interleukin 17 (IL-17) and RARrelated orphan receptor gamma (RORγt)62-67. Several studies in mice and humans describe
upregulation or activation of Th-associated transcription factors in Foxp3+ Tregs during
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regulation of Th1, Th2, or Th17 immune responses, suggesting that Tregs differentiate into
specialized subsets to modulate these responses57, 68-70. Furthermore, pro-inflammatory cytokine
production is associated with Th-like Treg subsets, despite the maintenance of suppressive
activity and stable Foxp3 expression57, 71-73. To describe these subsets of Foxp3+ Tregs in
humans and mice, the terms Th1-like, Th2-like, and Th17-like have been posited to refer to
Tregs with Th-associated phenotype or function57. An ongoing difficulty in the study of Treg
biology, particularly in vivo, is the lack of known surface markers to distinguish between subsets.
However, recent studies of human Tregs demonstrate that the surface phenotype of Treg subsets
corresponds to their effector counterparts, providing a means by which to identify and isolate
specific populations57, 73.
Chemokine Receptors and T cell Trafficking
In addition to the expression of cytokines and transcription factors, effector T cell subsets
express different chemokine receptors which, along with adhesion molecules, mediate the ability
to migrate to peripheral tissues and sites of inflammation74. Mature, naïve T cells exit the
thymus and primarily migrate to the blood and secondary lymphoid tissues, where they
encounter antigen presented by APCs and become activated75. Subsequently, effector T cells are
generated which mount a short-lived immune response in peripheral tissues while long-lived
memory T cells migrate to tissues to participate in immune surveillance74. Differential
expression of chemokine receptors on T cell subsets mediate migration to inflamed tissues as
well as trafficking to lymph nodes76 In this way, chemokine receptor expression directs specific
types of T cells to appropriate tissues and controls the type of immune response mounted against
a particular pathogen. For this reason, expression of chemokine receptors can be used not only
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to distinguish types of T cells, but also which tissues they localize to. Th1 cells, for example,
preferentially express CXC chemokine receptor 3 (CXCR3) in contrast to Th2 cells which
express CC chemokine receptor 3 (CCR3) and CCR477, 78. Th17 cells, on the other hand, express
CCR4 and CCR6 which mediate migration to sites of Th17 inflammation and, in particular, entry
into the central nervous system (CNS) in animal models of immune-mediated
neuroinflammation79, 80. CCR10, in combination with CCR4 and CCR6 is associated with skinhoming T cells, illustrating the importance of complex chemokine receptor signaling in
determining the migratory ability of T cells81. Finally, CCR7 confers the ability to migrate to
secondary lymphoid tissue and its expression is associated with naïve and central memory T
cells74. Like conventional T cells, Tregs express chemokine receptors which control tissue
localization and migration in response to inflammation82. Maintenance of immune homeostasis
in peripheral tissues is dependent upon colocalization of Tregs with effector T cells, meaning
that Tregs respond to chemokines in the same manner as conventional T cells83, 84. Furthermore,
ex vivo analysis of chemokine receptor expression by human Foxp3+ Tregs reveals the existence
of distinct subsets which closely resemble effector T cell subsets despite in vitro suppressive
activity57. Together, these studies suggest Tregs are functionally specialized to regulate immune
responses by localizing with effector T cells in vivo.
Fetal Tolerance and Neonatal Immunity
For humans and other placental mammals, pregnancy presents a significant
immunological challenge for both the maternal immune system and the developing fetus. The
maternal immune system must tolerate foreign antigens the fetus inherits from the paternal
genome while the developing fetus must remain tolerant to maternal antigens that cross the
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placenta85, 86. While development of T cells in mice is delayed, in the human fetus T cells can be
detected in peripheral lymphoid tissue by 10 weeks of gestation, necessitating tolerance early in
pregnancy87. Tregs are critical to maintaining tolerance at the fetomaternal interface, as antigens
are exchanged between mother and fetus throughout pregnancy88. In the mother, T cells do not
differentiate to pathogenic effector cells, but rather preferentially differentiate to Tregs and
expand in response to fetal antigens89-91. Notably, maternal Tregs specific for fetal antigen
persist after delivery and rapidly expand upon subsequent pregnancy89. The importance of Tregs
during pregnancy is illustrated by cases of deficient Treg expansion, which result in spontaneous
abortion and preecalmpsia92-94. The fetus also depends upon Tregs to maintain tolerance in
response to maternal antigens and cells that cross the fetomaternal interface86. Although T cells
are present in fetal lymphoid tissues early during development, the fetal adaptive immune system
was long considered immature, and therefore unresponsive to antigen95, 96. However, as early as
1945, seminal experiments demonstrated that antigens encountered in utero induced long-lasting
tolerance, suggesting an active immunosuppressive response1, 2. Furthermore, the fetal immune
system is highly responsive to stimulation under some conditions, and mounts adaptive immune
responses in response to certain pathogens97, 98. Recent studies demonstrate that a high frequency
of Tregs in fetal lymphoid tissues are responsible for dominant, tolerant responses observed
during antigen exposure in utero86, 99.
By the time of birth, frequencies of peripheral blood Tregs are comparable to adult,
however naïve T cells in neonates and infants display an enhanced propensity to differentiate to
Tregs rather than conventional T cells100. In agreement, studies of human umbilical cord blood
demonstrate elevated Treg generation in response to antigen stimulation, suggesting an intrinsic
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bias toward tolerance that persists into early life101. Birth presents an immense challenge to the
newborn, requiring maintenance of tolerance to avoid damaging responses to environmental
antigens and commensals while also necessitating protective immune responses against
pathogens102. For this reason, neonatal immunity is dependent upon plasticity to adapt to the
complex demands of early life102. In addition, newborns mount immune responses differently
from adults, including the well-documented bias toward Th2 responses and absence of Th1
responses103, 104. Despite a downregulation of antibacterial Th1 responses, newborns display
enhanced production of interleukin 8 (IL-8) by CD4+ and CD8+ T cells, a cytokine known to
potently activate and recruit antimicrobial neutrophils105. In contrast, IL-8 production by T cells
in adults is rare, perhaps representing a unique adaptation of the neonatal immune system to
early life105. Infectious disease remains a significant threat to newborns and neonatal infection
results in high morbidity and mortality even in the developed world106. Despite this, neonatal
immunity remains poorly understood. Understanding the balance between tolerance and
inflammation is critical to preventing newborn mortality and improving outcomes of vaccination
in early life102.
Tumor Necrosis Factor Biology
Tumor necrosis factor (TNF) was first discovered in 1975 and named for its ability to
induce necrosis of tumors in vitro107. Not long after, studies in mice demonstrated efficacy
against both human and murine tumors in vivo108. Expression of TNF was identified in
monocytes, macrophages, and activated T cells109, 110. Recombinant TNF was quickly moved
into clinical trials, where minimal anti-tumor effects were far outweighed by massive side effects
and toxicity111. Subsequently, studies in mice led to the observation that immunization against
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TNF protected mice from lethal effects of endotoxin, demonstrating for the first time that TNF
mediated inflammation112. Over the past 30 years, a wide range of activities have been attributed
to TNF, revealing diverse functions and solidifying TNF as perhaps the most pleiotropic
cytokine known today111.
TNF signaling.
TNF is produced as a 26 kDa type II transmembrane protein by macrophages, monocytes,
microglia, and activated NK and T cells113. The membrane form of TNF (mTNF) arranges in
homotrimers and is released to the soluble form (sTNF) via proteolytic cleavage by the
metalloprotease TNF alpha converting enzyme (TACE)114, 115. Soluble TNF circulates in blood
and elicits potent responses at distant sites while mTNF signals locally through cell-cell
contact111. Both forms of TNF bind two transmembrane receptors with distinct functions; TNF
receptor 1 (TNFR1 or CD120a) contains a death domain and induces cell cycle arrest and
apoptosis while TNF receptor 2 (TNFR2 or CD120b) promotes cell growth and survival116.
Importantly, the membrane form of TNF signals more potently than sTNF via TNFR2117.
Expression of TNFR1 is ubiquitous, expressed at low levels in most cell types and tissues, while
TNFR2 expression is limited to lymphoid and myeloid cells118. mTNF can also signal back to
the TNF-expressing cell when ligated with TNFR, resulting in phosphorylation of intracellular
domains and activating nuclear factor-kB (NF-κB) to modulate cytokine responses in a process
called reverse signaling119, 120.
TNF in human disease.
The role of TNF in inflammation is well established, and inhibition of TNF in treatment
of inflammatory diseases is common and efficacious121. Monoclonal antibodies or soluble
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receptors against TNF are particularly effective in patients with rheumatoid arthritis (RA) and
inflammatory bowel disease122, 123. However, some patients treated with TNF inhibitors
experience the onset or exacerbation of inflammatory diseases including psoriasis, uveitis, and
Crohn’s disease124. In addition, studies of inflammatory bowel disease in mice demonstrate that
colonic inflammation is paradoxically enhanced in TNF knockout animals125. Furthermore,
treatment of multiple sclerosis (MS) patients with anti-TNF therapy resulted in exacerbation of
disease symptoms126. These unexpected complications suggest that TNF mediates antiinflammatory effects as well as promoting inflammation.
TNF is reported to inhibit the function of Foxp3, thus reducing suppressive function of
Tregs isolated from RA patients127, 128. However, another study reports that suppressive activity
of Tregs is not affected by TNF129. In addition, TNF promotes proliferation of Tregs and
enhances Treg differentiation by suppressing Th17 generation130, 131. These contradictory results
suggest that TNF signaling in Tregs is complex and probably dependent upon experimental
approach. Tregs express TNFR2 and require TNFR2 signaling for stability of Foxp3 expression
and suppressive activity132-135. Furthmore, mTNF preferentially signals via TNFR2, indicating
that contract-dependent TNF signaling may be crucial to immunosuppressive responses117. The
impact of TNF on Treg function and stability remains controversial. Therefore, the role of
mTNF on Treg biology must be elucidated in order to understand paradoxical responses to antiTNF therapeutics in human disease.

CHAPTER TWO
MATERIALS AND METHODS
Mononuclear Cell Isolation and Cell Purification
Umbilical cord blood samples were collected from healthy volunteer donors into citrate
phosphate dextrose solution. Adult samples were collected from healthy volunteer donors into
heparin solution. Mononuclear cells were isolated by density gradient centrifugation using
Lymphocyte Separation Medium (Corning). Red blood cells were lysed using ACK lysis buffer
(Gibco). Adult Tregs and CD4+CD25- T cells were isolated from mononuclear cells using
EasySep Human CD4+CD127lowCD25+ Regulatory T Cell Isolation Kit (Stem Cell
Technologies). For mouse experiments, T cells were isolated from spleens of C57BL/6 mice and
enriched for CD4+ cells using mouse CD4+ T cell enrichment kit (Stem Cell). Naïve T cells for
suppression assay were obtained by FACS sorting for CD3+CD45RA+ and APCs by sorting for
CD3- cells.
Treg Induction
Umbilical cord blood mononuclear cells were stimulated with α-CD3 (200 ng/ml unless
otherwise stated) in the presence of IL-2 (10 ng/ml) in RPMI 1640 (Hyclone) supplemented with
10% fetal calf serum. Cells were cultured for 14 days with change of media every 2-3 days,
maintaining IL-2 concentration throughout culture duration. Tregs were analyzed on day 14
14
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after stimulation. For Th1 polarization cultures, IL-12 (20 ng/ml) was maintained in culture
medium. For Th17 polarization cultures, IL-1β (20 ng/ml) and IL-6 (20 ng/ml) were maintained
in culture medium. Recombinant human cytokines were obtained from Peprotech.
Antibodies
Antibodies used for flow cytometry were anti-CD4, CD8, CD25, Foxp3, CCR4, CCR6,
CCR7, CCR10, CXCR3, TNFR2, TIM-3, CD27, CD26, OX40, CD31, IL-2, GM-CSF, IFN-γ,
TNF-α, and IL-8 from Biolegend. Anti-TNFR1 was from Bio-Rad. Functional antibodies for
cell culture were anti-CD3 (OKT3), TNF-α (Mab11), IL-2, and CD28 from Biolegend.
Antibodies against mouse CD4, CD25, Foxp3, and TNF were obtained from Biolegend.
Flow Cytometry
Single cell suspensions were prepared in phosphate buffered saline with 0.5% fetal calf
serum and 0.01% sodium azide. Staining was performed according to standard protocols. Prior
to surface staining, cells were blocked with Human TruStain FcX blocking solution (Biolegend).
Foxp3 staining was performed using Foxp3 Fix/Perm buffer set (Biolegend). For cytokine
staining, cells were restimulated for 4 hours using phorbol myristate acetate (PMA; 50 ng/ml)
and ionomycin (1 µM; Sigma Aldrich) in the presence of monensin (1 µM; Biolegend) in RPMI
1640 (Hyclone) supplemented with 10% fetal calf serum. For surface TNF-α analysis,
stimulation was performed without monensin. Data were collected on FACS Canto II and LSR
Fortessa (BD Biosciences) and analyzed by Flowjo software (Tree Star).
Suppression Assay
Adult Treg cells were enriched by magnetic sorting as described above . Naïve T cells
and APCs were FACS sorted as previously described. Cord blood assays used total cord blood
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from Treg induction cultures. Prior to stimulation, Tregs were labeled with Cell Trace Violet
(Thermo Fisher) and naïve T cells labeled with CFSE (Thermo Fisher). 100,000 Tregs, 100,000
naïve T cells, and 50,000 APCs were added to a 96-well tissue culture-treated plate and
stimulated with 5 µg/ml anti-CD3 for 5 days. Data collected on FACS Canto II.
Survival Assay
Adult Tregs were isolated from peripheral blood and isolated by magnetic sorting as
previously described. Cells were labeled with CFSE and 100,000 cells added to each well of 96well non-tissue culture-treated plate coated with anti-CD3. Costimulation was provided by 5
µg/ml anti-CD28. IL-2 (10 ng/ml) was provided to control wells only and all other conditions
were treated with low endotoxin azide-free (LEAF) grade anti-IL-2 antibody (2 µg/ml). LEAF
grade anti-TNF or isotype control LEAF mIgG1 (25 µg/ml) were added as indicated. After 5
days, cells were counted in triplicate in 0.1% trypan blue solution in PBS. Average cell number
was calculated from triplicate values and divided by cell number of untreated control to generate
plotted data. Apoptosis was assessed by staining with annexin V (BD Biosciences) and
measured by flow cytometry.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism software. For TNF and IFN-y
expression were analyzed by student’s t-test (p<0.05). Treg survival assay was analyzed by
paired t-test (p<0.05).

CHAPTER THREE
PROPENSITY FOR TREG GENERATION BY CORD BLOOD NAÏVE T CELLS
Introduction
Umbilical cord blood and adult blood display a similar frequency of Tregs, however
naïve T cells from cord blood display an enhanced propensity for Treg differentiation when
stimulated ex vivo in the presence of IL-2 (Lee et al., manuscript in preparation). Tregs can be
generated from naïve T cells in peripheral tissues or in cell culture through TCR stimulation in
the presence of TGF-β and IL-246. Previous work demonstrates that CD14+CD36hi monocytes
in cord blood provide TGF-β and retinoic acid to naïve T cells, resulting in the majority of CD4
and CD8 T cells differentiating to Foxp3+ Tregs when stimulated in the presence of exogenous
IL-2 (Lee et al., manuscript in preparation).
Recognition of cognate antigen in the context of MHC is critical for T cell activation and
differentiation. Furthermore, many factors determine the fate of T cells during activation
including affinity of TCR for antigen in the context of MHC, the extent of TCR ligation,
costimulatory signals provided by antigen presenting cells (APCs), and the local cytokine
environment58, 136. In order to understand the in vivo role of cord blood Tregs, it is first
important to gain an understanding for the factors that influence differentiation of naïve T cells
from cord blood. For these reasons, we tested the impact of TCR stimulation strength and T
lineage-polarizing cytokines on the differentiation of naïve T cells from cord blood.
17
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The Role of TCR Signaling in Treg Generation
Outside the thymus, TCR ligation is required for differentiation of Tregs46. Numerous
studies indicate affinity of antigen is an important determinant for T cell differentiation, and low
dose, high affinity antigen is recognized as a potent driver of Treg generation in vivo137, 138.
Furthermore, the extent of TCR ligation is known to determine differentiation of naïve T cells
into specific lineages of effector T cells136. However, the precise role of TCR ligation in Treg
differentiation remains poorly understood.
To avoid the requirement for specific antigen, naïve T cells in cord blood were stimulated
with monoclonal antibodies against CD3, the signaling domain of TCR. In this manner, APCs to
provide costimulatory signals and cytokines as would occur in vivo. However, the extent of TCR
ligation as modeled by binding of anti-CD3 presented by APCs may impact the fate of T cells.
Specifically, we aimed to address whether the extent of TCR ligation in ex vivo stimulated T
cells in cord blood affects their differentiation into Tregs. To determine this, several doses of
anti-CD3 were tested and differentiation of cord blood T cells measured by flow cytometry.
Human T cells transiently express low levels of Foxp3 upon antigen stimulation, so cells were
expanded with change of media for 14 days to ensure that cells staining positive for Foxp3 were
stable Tregs32. We found that decreasing concentrations of anti-CD3 antibody reduced total
Foxp3 expression in both CD4 and CD8 subsets, indicating that less TCR stimulation decreases
T cell differentiation to Foxp3+ cells (Fig. 1).
To ensure that changes in Foxp3 expression were not due to lack of TCR stimulation at
low concentrations of anti-CD3, total cell numbers were calculated at the end of 14 day culture
period. Below 200 ng/ml anti-CD3, a two-fold reduction in cell number was found (Fig. 2).
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Together, these data indicate that higher doses of TCR stimulation promote Foxp3 expression.
Notably, even at low doses of stimulation the majority of CD4 and CD8 T cells express Foxp3.

Figure 1. Decreasing anti-CD3 reduces Foxp3 expression. Cord blood T cells stimulated with
decreasing concentrations of anti-CD3 and stained for Foxp3 after 14 days. Data plotted are
means of Foxp3+ frequency from 11 donors. Error bars indicate standard error of the mean.
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Figure 2. Effect of anti-CD3 concentration on T cell proliferation. Total cell number
calculated 14 days after anti-CD3 stimulation of naïve T cells from cord blood. Data are means
of 11 donors. Error bars indicate standard deviation.
Plasticity of Cord Blood Naïve T Cells in Response to Polarizing Cytokines
Differentiation of naïve T cells into effector lineages is dependent upon local cytokine
milieu during activation58. In the presence of IL-2, naïve T cells from cord blood upregulate
Foxp3 and differentiate to functionally suppressive Tregs. Previous work demonstrates that the
addition of exogenous IL-4 potently blocks Treg differentiation by cord blood T cells (Lee et al.,
manuscript in preparation). However, the plasticity of naïve T cells from cord blood in response
to other lineage-polarizing cytokines remains unresolved. For this reason, we investigated the
impact of Th1 and Th17 polarizing conditions on cord blood Treg differentiation.
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Cord blood T cells readily upregulate Foxp3 and become Tregs in response to ex vivo
stimulation, a propensity that is maintained in the infant throughout the first year of life139. Like
Treg differentiation, generation of inflammatory Th17 cells is dependent on TGF-β140. However,
while IL-2 promotes Foxp3 expression, Th17 differentiation is driven by the presence of
inflammatory cytokines. Specifically, IL-6 and IL-1β are known to drive RORγt and IL-17
expression, which are key identifiers of inflammatory Th17 cells141, 142. Cord blood T cells fail
to proliferate in the absence of IL-2 (data not shown), so the capacity for Th17 differentiation
was tested by adding recombinant IL-6 and IL-1β to naïve T cells in the presence of exogenous
IL-2. If Th17 differentiation occurred, we expected to see a decrease in Foxp3+CD25+ cells.
After 14 days, Treg phenotype was assessed by flow cytometry after staining for Foxp3 and
CD25. Addition of Th17-polarizing cytokines had no effect on the expression of these markers
by CD4+ or CD8+ cells, indicating that Treg differentiation was not affected in either subset
(Fig. 3). Furthmore, Th17 differentiation was assessed by intracellular staining for RORγt,
revealing no difference between Treg-induced (IL-2 alone) and Th17-induced (IL-2+IL-1β+IL6) conditions (data not shown). To test for IL-17 expression, Treg and Th17-induced cells were
restimulated with PMA/ionomycin and culture supernatants assessed for soluble IL-17 by
cytometric bead array. IL-17 was not detected in either condition, confirming the absence of
Th17 differentiation by cord blood T cells (data not shown).
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Figure 3. Treg differentiation in response to Th17 and Th1 polarizing cytokines. Cord
blood mononuclear cells stimulated with anti-CD3 in the presence of indicated cytokines for 14
days. Data shown are representative of 3 donors. Data generated by size gating on live cells,
then gating on CD4+ and CD8+ groups.
To test the plasticity of cord blood naïve T cells in response to Th1 polarizing conditions
in vitro, recombinant human IL-12 and IL-2 were added to cord blood mononuclear cells at the
time of stimulation and maintained throughout culture duration. Differentiation of Tregs was
assessed by the expression of Foxp3 and CD25 using flow cytometry. After 10 days in culture,
cessation of growth became evident in cells treated with IL-12, and by day 14 after stimulation
cells exhibited widespread death. Flow cytometric analysis revealed markedly reduced
expression of Foxp3 and CD25 in both CD4+ and CD8+ populations, indicating a reduction in

23

Treg differentiation in IL-12-treated samples (Fig. 3). Alternatively, reduction in Foxp3
expression in live-gated cell groups may be due to loss of expression by apoptotic cells.
Discussion
Th1 helper cells are critical for immune responses against intracellular bacteria. IL-12
and IL-2 drive Th1 differentiation, upregulating T-bet expression and the signature cytokine
IFN-γ, which activates macrophages to kill intracellular bacteria58, 60. Appropriate immune
responses to intracellular bacteria require differentiation of naïve T cells in response to
polarizing cytokines, thus inducing expansion of Th1 effector cells in response to infection.
Studies in mice and human cord blood naïve T cells demonstrate reduced Th1 differentiation
compared with adult naïve T cells and a bias towards production of IL-4, IL-5, and IL-13 rather
than IFN-γ143-145. A bias toward Th2 immunity combined with a deficiency in cell-mediated
immunity make newborns susceptible to viral and bacterial infections and limit efficacy of
vaccination against intracellular pathogens146. Furthermore, differentiation of Tregs rather than
effector T cells may contribute to impaired immune responses to pathogens and vaccines. For
these reasons, understanding the extent to which cord blood naïve T cells differentiate to Tregs in
the presence of T helper-polarizing cytokines is crucial to improving outcomes for neonates in
response to infectious disease. We demonstrate that Th1-polarizing conditions reduce Foxp3
expression and Treg development in vitro. Furthermore, Th1-polarizing cytokines resulted in
cell death and reduced expansion in response to TCR stimulation. Th1 cytokines may promote
cell death or attenuation of proliferation in newborns, contributing to the paucity of Th1
immunity in early life. This possibility, however has not been directly tested. Future work will
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determine whether reduction in Foxp3 during Th1-polarization is associated with upregulation in
Th1 cytokines and T-bet expression.
In contrast, Th17-polarization had no effect on Treg generation. IL-2 is shown to block
Th17 differentiation, so the possibility remains that IL-2 addition inhibited Th17 generation147.
Without IL-2, however, cord blood T cells fail to proliferate. In agreement with our results,
Th17 cells are not readily detected in the peripheral blood of infants and only begin to
differentiate after the first few months of life139. The propensity for Treg generation observed in
cord blood and neonates may block Th17 differentiation, resulting in a tolerant, rather than proinflammatory, immune status.
The effect of antigen dose was modeled by stimulation with variable concentrations of
anti-CD3, revealing a relationship between antigen dose and Treg differentiation. We observe a
correlation between concentration of anti-CD3 and frequency of cells expressing Foxp3,
suggesting that the extent of TCR ligations impacts cell fate during stimulation. Interestingly,
even the lowest doses of anti-CD3 resulted in Foxp3 expression in a large fraction of cells,
demonstrating the propensity for Treg generation by cord blood T cells. The role of antigen
affinity on Treg generation, however, was not tested. Anti-CD3 stimulates TCR signaling, and
therefore concentration of anti-CD3 affects the amount of TCR complexes activated, but does
not directly provide any information about antigen affinity in Treg generation.
Together, these results demonstrate a propensity for Treg generation in cord blood that is
at least partially affected by extent of TCR ligation. Furthermore, we demonstrate a failure to
reduce Treg differentiation in response to inflammatory cytokines reported to induce Th17 cells.
Therefore, in agreement with other studies, Treg differentiation may predominate neonatal
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responses to antigen while Th17 inflammatory responses are absent. Th1-polarizing conditions,
however, reduced Foxp3 expression and resulted in reduced growth and subsequent cell death.
While the mechanism by which IL-12 attenuates growth and induces cell death was not tested,
this phenomenon may represent a means by which the neonatal immune system avoids Th1
responses.

CHAPTER FOUR
PHENOTYPE OF CORD BLOOD TREGS IN COMPARISON TO ADULT PERIPHERAL
BLOOD TREGS
Introduction
Cord blood naïve T cells readily differentiate to regulatory T cells after ex vivo
stimulation and exhibit in vitro suppressive activity comparable to adult peripheral blood Tregs.
However, recent studies demonstrate the existence of several distinct subsets of Foxp3+ Tregs
with distinct functions in controlling immune responses57. Tregs suppress T cell proliferation
primarily by direct contact, and therefore tissue localization is critical to Treg function in vivo 43.
Therefore, analysis of chemokine receptor expression by cord blood Tregs is pivotal to
predicting compartmentalization to peripheral tissues during immune responses in neonates.
Furthermore, subsets of Tregs in adult peripheral blood have been identified and distinguished by
differential expression of chemokine receptors57. These subsets display surface phenotypes
similar to effector T cell subsets and even share expression of characteristic pro-inflammatory
cytokines when stimulated ex vivo 57. Cell surface molecules are important not only to the
phenotypic classification of cell types and subsets, but also to a multitude of important cellular
functions. Specific molecular interactions between immune cells during cell-cell contact is
crucial for many aspects of immune cell function, and T cells express various costimulatory and
immune checkpoint molecules to regulate activation, proliferation, and survival148. While adult
peripheral blood Tregs have been investigated extensively, little is known about Tregs in fetal or
26
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neonatal immunity. To understand the function of cord blood Tregs in neonatal immunity, the
surface phenotype and cytokine profile must first be determined.
Cord Blood Tregs Express Chemokine Receptors and are Distinct from Adult tTregs
To characterize the phenotype of umbilical cord blood-derived Tregs, we compared
chemokine receptor expression to Tregs isolated from adult peripheral blood (tTregs). Adult
tTregs expressed high amounts of CCR4 and CCR6 and the majority were
CCR4+CCR6+CCR7loCXCR3+/- (Fig. 4). In contrast, cord blood CD4+ Tregs expressed lower
amounts of CCR4 and CCR6, but exhibited elevated CCR7 expression in comparison to adult.
The phenotype CCR4loCCR6loCCR7+CXCR3+ was shared between CD4+ and CD8+ UCB Tregs,
although CD8+ Tregs expressed less CCR4. Furthermore, while only a subset of adult Tregs
expressed CXCR3, the majority of cord blood CD4+ and CD8+ Tregs expressed CXCR3.
Finally, low CCR10 expression was only observed in CD8+ cord blood Tregs.
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Figure 4. Chemokine receptor expression by cord blood and adult Tregs. Flow cytometric
analysis of Tregs from adult peripheral blood and umbilical cord blood. Data shown are
representative of 5 independent experiments. Dashed lines indicate isotype controls.

Cord Blood Tregs Express Distinct Surface Antigens
To investigate functional differences between cord blood-derived Tregs and adult tTregs,
we compared expression of surface antigens associated with T cell function. In particular, we
tested the expression of surface molecules involved in T cell activation or contact-dependent
interactions with other immune cells. We found that cord blood and adult Tregs shared high
expression of CD27, a costimulatory surface receptor known to be critical for T cell expansion
and formation of immunological memory149, 150 (Fig. 5). To further analyze surface antigen
expression, CD4+ and CD8+ populations were further gated on Foxp3+CD27+ groups. Strikingly,
we found high expression of CD26 on both CD4+ and CD8+ Tregs from cord blood, but in
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contrast adult Tregs were all CD26-. We also tested the expression of surface receptors involved
in T cell activation and immune regulation. We found that a fraction of CD8+ Tregs from cord
blood express TIM-3 (~60%) in addition to a smaller fraction of CD4+ Tregs (~15%). In
contrast, adult Tregs showed no expression of TIM-3. Additionally, expression of the TNF
receptor superfamily molecule OX40 was detected on a group of CD4+ cord blood Tregs
(~40%), but not on CD8+ cord blood Tregs or adult tTregs. Finally, nearly all CD8+ Tregs from
cord blood expressed the platelet adhesion molecule CD31, in addition to a subset (~30%) of
cord blood CD4+ Tregs. CD31 was not detected on adult Tregs. Together, these results
demonstrate a surface antigen phenotype in cord blood Tregs that contrasts with adult CD4+
Tregs, suggesting cord blood Tregs possess distinct functions not observed in adults.
Furthermore, phenotypes differed between CD4+ and CD8+ Tregs in cord blood, providing
further evidence for functional specialization of these subsets.
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Figure 5. Surface antigen expression by cord blood and adult Tregs. Cord blood-derived
Tregs and adult peripheral blood Tregs stained for surface antigen expression. Samples gated on
total CD4+ or CD8+ populations prior to gating on Foxp3+CD27+ for further analysis.
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Cord Blood Tregs Express Distinct Cytokine Profile
Recent reports demonstrate inflammatory cytokine production by subsets of human
Tregs57. To assess possible functions for cord blood-derived Tregs in vivo, we tested the ability
of these cells to produce cytokine. Naïve T cells were induced to generate Tregs as previously
described, then restimulated with PMA and ionomycin in the presence of monensin to induce
activation and cytokine expression while blocking golgi transport to prevent secretion of
cytokines. Subsequently, cytokines were detected by intracellular staining along with Foxp3 costaining and analyzed by flow cytometry. We found that cord blood Tregs express a distinctive
profile of cytokines (Fig. 6A). Foxp3+ CD4+ cells produced TNF (>80%), IL-2 (~30%), GMCSF (~50%), and IL-8 (~30%). Similarly, Foxp3+CD8+ Tregs from cord blood expressed TNF
(>80%), GM-CSF (~70%), and IL-8 (~20%). CD8+ Tregs did not express IL-2, but expressed
IFN-γ (25%). Expression of IL-10 and IL-17 were not detected (data not shown). The majority
of CD8+ Tregs from cord blood expressed both IL-8 and GM-CSF, while a fraction (~20%) of
cord blood CD4+ Tregs expressed both cytokines (Fig. 6B). In contrast, conventional adult T
cells (CD4+CD25-Foxp3-) display subsets of IL-8 or GM-CSF producing cells (~10%), however
the production of these cytokines were mutually exclusive. Furthermore, Foxp3+ Tregs from
adult blood did not express the cytokine profile of cord blood Tregs. Unexpectedly, however,
TNF expression was observed in the majority of adult Foxp3+ Tregs (>70%). These data
demonstrate distinct cytokine profile differences for cord blood Tregs in comparison to adult
Tregs. Furthermore, cytokine expression by cord blood Tregs supports functional differences for
cord blood Tregs, suggesting Tregs in cord blood are able to mediate both anti-inflammatory and
pro-inflammatory immune responses.
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Figure 6. Distinct cytokine profile of cord blood Tregs. Cord blood and adult Tregs
stimulated with PMA and ionomycin for 4 hours in the presence of monensin. (A) Cytokine
profile of cord blood and adult Tregs (B) Co-expression of IL-8 and GM-CSF by cord blood
Tregs in contrast to adult Tregs (CD4+CD25+Foxp3+) and conventional T cells (CD4+CD25Foxp3-). Representative data from 6 donors for cord blood Tregs, and 3 donors for adult
samples. (C) Frequency of cells staining positive for cytokines. Cells gated on CD4 or CD8 as
indicated, followed by gating on Foxp3+ and Foxp3- populations prior to cytokine analysis. For
adult samples, Foxp3+ were also gated on CD25+ and Foxp3- are gated on CD25-. Bars
represent means of each sample.

Discussion
Chemokine receptor expression.
Cord blood Tregs express a distinct phenotype of chemokine receptor expression in
comparison to adult Tregs, suggesting differential roles in tissue localization and trafficking
ability. Expression of CXCR3 is limited predominantly to Th1 cells and mediates migration to
sites of inflammation in response to CXCR3 ligands CXCL9, CXCL10, and CXCL11151.
Recently, a subset of Th1-like CXCR3+Foxp3+ Tregs have been identified in adult peripheral
blood with the ability to express IFN-γ and suppress Th1-mediated immune responses57. In
support of this, we observe a small population of CXCR3+ Tregs in adult peripheral blood. In
contrast, however, the majority of CD4+ and CD8+ Tregs in cord blood express CXCR3,
suggesting a role for these cells in suppressing Th1 immune responses and localizing to sites of
Th1-mediated inflammation. During fetal development and early life, Th1 responses are mostly
absent with the exception of responses to specific pathogens146. In utero, Th1 responses are
toxic to the placenta and may result in termination of pregnancy152. Therefore, expression of
CXCR3 by Tregs during fetal development may be important to control Th1 responses by
trafficking to sites of Th1 inflammation and suppressing T cell proliferation and cytokine
production.
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Elevated CCR7 expression distinguishes cord blood Tregs from adult. CCR7 is required
for T cell trafficking from peripheral tissues to lymphoid tissue in response to CCL19, the ligand
for CCR7153. CCL19 is expressed in T-cell zones in lymphoid tissue, suggesting a role for
CCR7+ Tregs in modulation of T cell activation in germinal centers154.
While adult peripheral blood Tregs are known to express high levels of CCR4 and CCR6,
expression of these receptors was reduced in cord blood Tregs155. CCR4+ Tregs are associated
with residence in epithelial tissue, and in mice the loss of CCR4 in Tregs results in lymphocyte
infiltration and inflammation in skin and lungs84. Expression of CCR6 mediates migration of
both Th17 and Treg cells to areas of inflammation, suggesting a role of CCR6+ Tregs in
suppressing Th17-mediated inflammation156. Decreased expression of CCR4 and CCR6 on cord
blood Tregs in comparison to adult suggests a diminished ability to migrate to epithelial tissue
and sites of Th17-mediated inflammation, however this hypothesis has not been tested.
Together, these data demonstrate a distinct phenotype of cord blood Tregs in comparison
to adult and suggest that cord blood-derived Tregs would migrate differently than tTregs during
immune responses and inflammation.
Surface antigen phenotype.
CD26, also known as dipeptidyl peptidase 4 (DPPIV), is a surface antigen associated
with T cell activation and possesses enzymatic activity157. CD26 can cleave a variety of
hormones, growth factors, and chemokines which share proline or alanine residues at the Nterminus, thus modulating many physiologic processes including immune regulation and
responses to infection157. In particular, adenosine deaminase (ADA) is a known substrate for
CD26158. ADA is involved in purine metabolism and immune homeostasis, and genetic

36

deficiencies in ADA result in severe combined immune deficiency (SCID) and eventually
death159. As our data corroborate, CD26 is not expressed on adult Tregs, but in contrast we
demonstrate high expression on cord blood Tregs, suggesting an important role for this enzyme
in fetal or neonatal immune regulation or development160. Future work will determine whether
CD26 expression by cord blood Tregs modulates fetal or neonatal immune responses.
Expression of TIM-3 is associated with Th1 cells in humans and regulates Th1 cytokine
production as well as maintenance of tolerance in vivo 161. Specifically, interaction of TIM-3
with TIM-3 ligand is shown to inhibit Th1 responses in mice, thus maintaining peripheral
tolerance162. In humans, a paucity of TIM-3 expression is observed in multiple sclerosis (MS)
patients compared with healthy controls and blockade of TIM-3 increases IFN-γ secretion by
CD4+ T cells163. Furthermore, expression of TIM-3 on cytotoxic CD8+ T cells is associated with
anti-atherogenic cytokine production in human patients with atherosclerosis and blockade of
TIM-3 in this context aggravates inflammation164. Studies of tumor-bearing mice implicate
tumor-resident TIM-3+ Tregs in tumor progression, identifying TIM-3+ Tregs as highly
suppressive of effector T cell responses165. Together, these studies demonstrate the importance
of TIM-3 in the maintenance of tolerance in both human and murine disease. Expression of
TIM-3 on cord blood Tregs, particularly CD8+ Tregs, suggests an important immunoregulatory
role for this receptor. Future work will determine the function of TIM-3 in immune homeostasis
in early life.
TNF receptor superfamily members are highly conserved and control a wide variety of
immune responses166. One of these members, OX40, is important to regulation of CD4 and CD8
T cells responses as well as the differentiation and activity of regulatory T cells167. OX40 is
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expressed on activated T cells, where interaction with OX40 ligand (OX40L) on APCs induces
NF-κB activation, enhancing T cell survival and proliferation168. Ligation of OX40 with OX40L
has been shown to reduce Foxp3 upregulation to block Treg differentiation and inhibit
production of IL-10169, 170. An interesting, but untested, possibility is that expression of OX40 on
a subset of cord blood CD4+ Tregs may be a mechanism to limit Treg differentiation in neonates.
CD31, or platelet endothelial cell adhesion molecule-1, is a transmembrane receptor
expressed on a variety of immune cells, endothelial cells, and platelets171. While the precise role
of CD31 in Treg function has not been elucidated, some studies link CD31 expression to
reduction in T cell activation and proliferation and others demonstrate a loss of Treg-mediated
suppression following loss of CD31 in vivo 172, 173. In addition, CD31 signaling is suggested to
limit clonal expansion by negatively regulating proliferation and inhibiting apoptosis171.
Expression of CD31 by cord blood Tregs, but not adult tTregs suggests that cord blood Tregs
may be responsive to signaling which adult Tregs are not. However, the function of CD31 in
neonatal immune homeostasis and Treg function remains unresolved.
Cytokine profile.
Cord blood Tregs exhibit potent suppressive activity in vitro but also produce
inflammatory cytokines known to activate innate immune responses. Granulocyte macrophage
colony-stimulating factor (GM-CSF) activates monocytes/macrophages and induces
differentiation to modulate immune responses in peripheral tissues174. Importantly, GM-CSF
induces monocytes to differentiate into inflammatory M1 macrophages rather than antiinflammatory M2 macrophages175. GM-CSF is produced by a variety of immune cells including
B and T cells, macrophages, neutrophils, and eosinophils176. Production of GM-CSF by T cells
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is associated with pathology in several human diseases and their mouse models. In MS and the
mouse model experimental autoimmune encephalomyelitis (EAE) CD4+ T cells drive
inflammation and tissue destruction, and specifically Th17 cells have been tied to pathology of
neuroinflammation176. However, studies in mice demonstrate IL-17 is not required for
development of EAE, but rather GM-CSF inhibition ameliorates progression of disease177. In
addition, production of GM-CSF by pathogenic T cells is associated with Th1 inflammation in
rheumatoid arthritis and Th2-mediated allergic lung disease176. Therefore, GM-CSF not only
regulates immune homeostasis, but also exacerbates inflammation. GM-CSF production by T
cells in cord blood may be important to differentiation of myeloid cells in responses to infection,
although this possibility has not been tested. Expression of GM-CSF by Tregs suggests a
multifunctional role for these cells, possibly negatively regulating adaptive immune responses
while simultaneously driving innate immune responses and inflammation. Future work will test
the ability of cord blood Tregs to induce M1 macrophage differentiation from monocytes.
Furthermore, previous work demonstrates the requirement for monocytes in the differentiation of
Tregs in cord blood (Lee et al., manuscript in preparation). Therefore, GM-CSF may induce
differentiation of monocytes and reduce Treg differentiation in favor of effector T cell generation
in a negative feedback loop to control Treg homeostasis in neonates.
IL-8 also mediates innate immunity, resulting in recruitment and activation of neutrophils
during immune responses178. Neutrophils serve as the first line of defense against many
pathogens, making IL-8 expression an essential aspect of initiation of immune responses during
infection179. In newborns, T cells readily produce IL-8 upon antigen encounter and infection,
however production of IL-8 by T cells is rare in adults105. Infants do not readily mount Th1
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immune responses, so IL-8 production may be a compensatory mechanism to recruit neutrophils
during bacterial infections. IL-8 production by Tregs has been identified in humans, and is
hypothesized to modulate the recruitment of immune cells to inflamed tissues180. Together, these
data suggest IL-8 production by Tregs may be important for effective defense against bacterial
infections in early life, recruiting neutrophils to peripheral tissues and activating innate
immunity.
Interferon gamma (IFN-γ) is produced by activated T helper and CD8+ cytotoxic T cells
in response to viral and bacterial infections181. Along with TNF, IFN-γ is considered a
prototypic Th1 cytokine and contributes to pathogen recognition while initiating antiviral
responses by inhibiting cell proliferation and inducing apoptosis181. Regulatory T cells are
generally considered unable to produce IFN-γ, however recently a subset of Th1-like Tregs have
been described by expression of IFN-γ during ex vivo stimulation57. We observe IFN-γ
expression by CD8+Foxp3+ Tregs from cord blood, suggesting these cells mediate immune
homeostasis in response to intracellular pathogens. Viral infections are particularly dangerous
during fetal development and in early life, with recent cases of Zika virus infections
demonstrating a paucity of antiviral immune responses in the fetus182. An interesting, but
untested possibility is that CD8+ Tregs suppress adaptive immune responses to prevent damaging
inflammation while modulating antiviral immunity by secreting IFN-γ during infection.
Both cord blood and adult Tregs robustly express TNF in response to stimulation. The
pro-inflammatory effects of TNF are well-described, however recent studies provide clear
evidence of anti-inflammatory roles for this pleiotropic cytokine. In mice, TNF is important to
development of inflammatory bowel disease. Paradoxically, however, TNF gene knockout
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results in more severe intestinal inflammation rather than reducing pathology. Similarly, in
humans inhibition of TNF in RA and Crohn’s disease patients results in onset of autoimmune
inflammation in some cases124. These results suggest an important role for TNF in immune
homeostasis that remains poorly understood. Expression of TNF by Tregs from both cord blood
and adult peripheral blood raises the possibility of an important function for TNF in Treg
homeostasis.
Together, these results suggest a multifunctional role for Tregs in fetal and neonatal
immunity. Expression of cytokines known to recruit and activate innate immune cells to sites of
inflammation, along with distinct chemokine receptor expression may allow Tregs to migrate to
peripheral tissues to control immune responses to pathogens. Tregs may be important to control
adaptive immune responses during development while simultaneously protecting the newborn
from infection by recruiting and activating macrophages and neutrophils.

CHAPTER FIVE
FUNCTION OF TUMOR NECROSIS FACTOR SIGNALING IN TREGS
Introduction
The observation of robust TNF expression by both cord blood and adult Tregs suggests
an important function for this cytokine. Recent reports disagree about the role of TNF-α
signaling on Tregs; some reports suggest that TNF-α selectively activates and expands Tregs via
tumor necrosis factor receptor 2 (TNFR2) while others indicate that TNF-α inhibits the
suppressive function of human Tregs127, 130. Furthermore, inhibition of TNF results in the onset
or exacerbation of autoimmunity in some patients124. However, expression of TNF by human
Tregs has not been reported. For these reasons we decided to investigate the function of TNF
produced by Tregs.
Effect of TNF on Treg Differentiation
TNF is reported to inhibit phosphorylation of Foxp3, therefore reducing suppressive
function of Tregs in rheumatoid arthritis (RA)127. However, other reports demonstrate a
requirement for TNF signaling via TNFR2 on Tregs for maintenance of highly suppressive Tregs
during inflammation134. TNFR2+ Tregs reportedly upregulate Foxp3 and proliferate in response
to TNF, suggesting a role of TNF in activation and expansion of Foxp3+ Tregs135. Furthermore,
interaction of transmembrane TNF (mTNF) with TNFR2 has been shown to block differentiation
of Th17 cells in favor of Treg differentiation131. To test the impact of TNF on
41
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Figure 7. Effect of TNF inhibition on cord blood Treg generation. Cord blood Tregs were
induced as previously described in the presence of anti-TNF, isotype control, or left untreated.
At day 14, Treg phenotype was assess by flow cytometry. Representative data from 4
experiments.

differentiation of Tregs, we used a neutralizing antibody against TNF to block TNF signaling
during differentiation of cord blood Tregs, expecting to see a reduction of Foxp3+CD25+ Tregs in
cultures treated with anti-TNF if TNF is important to Treg generation. However, we observed
no difference in differentiation of CD4+ or CD8+ Tregs from cord blood treated with anti-TNF,
and isotype control antibody (mIgG1), or those left untreated (Fig. 7). Although only one
concentration of anti-CD3 is shown above, concentrations as high as 25 µg/ml and as low as 40
ng/ml also had no effect on frequency of Tregs generated in vitro. Specifically, no change in
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total Foxp3 frequency was observed in CD4+ or CD8+ Tregs between conditions. Furthermore,
no change in Foxp3+CD25+ phenotype was observed. These results suggest TNF does not affect
cord blood Treg differentiation during induction in vitro.
Effect of TNF on Suppressive Activity of Tregs
TNF signaling has been linked to alterations in suppressive activity of Tregs, however
discordant results prompted us to investigate the impact of TNF inhibition on in vitro suppressive
activity of human Tregs127, 129. We tested the effect of TNF neutralization on suppression of
naïve T cell proliferation using a standard suppression assay. Induced Tregs from cord blood or
adult Tregs isolated from adult peripheral blood were mixed (1:1) with naïve T cells (adult
CD3+CD45RA+ FACS sorted after collection from peripheral blood) labeled with CFSE to track
cell division. Cells were stimulated by anti-CD3 antibody and APCs (CD3- FACS sorted after
isolation from peripheral blood), and after 5 days proliferation of naïve T cells was determined
by flow cytometric analysis of CFSE dilution. Naïve T cells and APCs were isolated from the
same donor as Tregs in experiments with adult Tregs. To discern between Tregs and naïve T
cells, Tregs were labeled with Cell Trace Violet (CTV) and removed from analysis by gating out
CTV+ cells. As a control for viability of naïve T cells, naïve T cells were stimulated with antiCD3 and APCs in the absence of Tregs. Both cord blood derived Tregs and adult peripheral
blood Tregs potently suppressed proliferation of naïve T cells, however no difference was
observed between cells treated with anti-TNF antibody and those treated with the isotype control
(Fig. 8). Neither cord blood nor adult Tregs exhibited a decrease in suppressive activity when
TNF was inhibited, however a slight increase in suppression was observed. This small increase
in suppression may be due to reverse signaling of mTNF when bound to anti-TNF, thus
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activating Tregs and mildly increasing suppression. Together these results suggest that in vitro
suppression of naïve T cell proliferation is not decreased by TNF inhibition.

Figure 8. Effect of TNF inhibition on suppressive activity of cord blood and adult Tregs.
Whole cord blood derived Tregs or adult Tregs isolated from peripheral blood were tested for
suppressive activity in the presence or absence of anti-TNF antibody. CFSE dilution in labeled
naïve T cells was determined by flow cytometry after 5 days.
Adult Foxp3+ Tregs Express Membrane TNF
TNF is expressed as a type II transmembrane protein and must be cleaved by TACE to
produce the soluble form113. Both membrane and soluble forms of TNF are active and can signal
via TNF receptors, however each form exhibits specific activity. Soluble TNF signals more
readily via TNFR1, while mTNF has a greater affinity for TNFR2117. TNFR1 contains an
intracellular death domain and signals for cell cycle arrest and apoptosis, while TNFR2 lacks a
death domain and activates NF-κB to promote growth and proliferation116. Due to the different
effects mediated by the two different forms of TNF, we investigated which cells in adult
peripheral blood express mTNF.
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Total adult PBMCs were collected and stimulated in vitro with PMA and ionomycin.
Expression of mTNF was detected by surface staining followed by analysis by flow cytometry.
We found that expression of mTNF was limited to CD4+CD25+ cells (Fig. 9A). In contrast,
CD4+CD25- cells did not express mTNF. Human T cells transiently express CD25 when
activated, but Tregs constitutively express high amounts of CD2536. To test whether Tregs
express mTNF, Tregs were isolated from PBMCs by magnetic sorting and stimulated.
Expression of mTNF on conventional T cells was compared by magnetic sorting for CD4+CD25cells followed by stimulation. To ensure mTNF expression by Foxp3+ cells, both enriched
populations were stained for TNF along with co-staining for CD4, CD25, and Foxp3 and
analyzed by flow cytometry. We found that mTNF expression was indeed limited to a group of
CD4+CD25+Foxp3+ cells, and found no mTNF expression on stimulated CD4+CD25-Foxp3- cells
(Fig. 9B). Although expression was low, greater than 50% of Foxp3+ T cells express detectable
mTNF. These results demonstrate mTNF is preferentially expressed by Tregs in comparison to
conventional T cells.
TNF is traditionally considered a Th1 cytokine, so as a control we assessed production of
the signature Th1 cytokine IFN-γ by Tregs. Total expression of TNF and IFN-γ were assessed
by intracellular staining with Foxp3 costaining. We found that Foxp3+ Tregs expressed TNF
when stimulated but did not express any IFN-γ (Fig. 9C). We also compared expression of TNF
and IFN-γ between Foxp3+ Tregs and conventional T cells. Total CD4+CD25-Foxp3- T cells
expressed IFN-γ and TNF, however Foxp3+ T cells did not express IFN-γ (Fig. 9D).
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Figure 9. Expression of TNF by human Foxp3+ Tregs
Adult peripheral blood T cells were stimulated by PMA plus ionomycin for 4 hrs in the presence
of monensin (details described in methods). The expression of cytokines was determined by
intracellular staining or surface staining and analysis by flow cytometry. (A) Expression of the
membrane form of TNF (mTNF) by CD4+CD25+ (right) and CD4+CD25- T cells (left).
Representative data from 4 donors. Dashed lines indicate unstimulated samples and solid lines
indicate stimulated samples (B) Expression of mTNF by CD4+CD25+Foxp3+ Tregs (left) or by
CD4+CD25-Foxp3- conventional T cells (right). A representative data set from three donors. (C)
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Expression of total TNF (upper panels) and IFN-y (lower panels) by unstimulated (left panels) or
stimulated (right panels) Foxp3+ Tregs by intracellular staining. A representative data set from
three samples. (D) Frequencies of TNF (left) or IFN-y(right) expressing cells among
CD4+CD25+Foxp3+ (Foxp3+) cells and CD4+CD25-Foxp3- (Foxp3-) cells. TNF (n=6), IFN-y
(n=3). * p<0.05 (student t test). (E) Expression of TNFR1 and TNFR2 on human Tregs by flow
cytometry. (F) Expression of mTNF (n=3) and total (intracellular) TNF (n=5) by mouse CD4+
T cells. Representative data sets from 2 experiments. Foxp3+ Tregs (left) were gated first on live
CD4+CD25+ cells, while Foxp3- T cells (right) were gated first on live CD4+CD25- cells.
Dashed lines indicate unstimulated samples and solid lines represent stimulated samples.

The anti-inflammatory effect of TNF has been described in mice as well as humans, so
we investigated whether TNF is expressed on mouse Tregs126. We isolated total splenic CD4+ T
cells from C57BL/6 mice and stimulated as previously described. Total TNF expression was
assessed by intracellular staining after stimulation in the presence of monensin while mTNF
expression was assessed by surface staining after stimulation without monensin. We found
similar expression of total TNF by Foxp3+ and Foxp3- T cells, however Foxp3+ T cells expressed
a greater amount of mTNF (Fig. 9F). Some Foxp3- T cells expressed detectable mTNF as well,
however expression was lower than in Foxp3+ cells. These data demonstrate that Foxp3+ Tregs
preferentially express the membrane form of TNF in both mice and humans, suggesting that antiinflammatory roles for TNF described in mouse and man may be related to mTNF expression by
Tregs.
Membrane TNF signals preferentially through TNFR2 and promotes survival and growth
rather than death. To investigate the possible outcomes of TNF signaling by Tregs, we assessed
the expression of TNF receptors by adult peripheral blood Tregs. In agreement with literature,
we found that Foxp3+ T cells express TNFR2 but not TNFR1 (Fig. 9E). These data suggest that
mTNF may signal Tregs for survival and proliferation via TNFR2 in an autocrine manner.
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Function of Treg-derived TNF
To test the hypothesis that mTNF signals Tregs for survival and proliferation in an
autocrine manner, we developed an assay to test survival of adult Tregs in response to TNF
inhibition. Tregs were isolated from peripheral blood, labeled with CFSE and stimulated ex vivo
with plate-bound anti-CD3 and soluble CD28 in the presence of anti-TNF neutralizing antibody
or isotype control. Importantly, IL-2 is considered a powerful growth factor for Tregs and is
required for their survival in vitro 20. Therefore, to test the impact of TNF on Treg survival
independent of IL-2, we did not add exogenous IL-2. Furthermore, we added a neutralizing
antibody against IL-2 to block any endogenous IL-2 production. As a control for cell viability
we included Tregs stimulated in the presence of IL-2. After 5 days, survival was assessed by
counting live cells. In the presence of TNF inhibition, survival was significantly reduced
compared to untreated cells (Fig. 10). Furthermore, increasing concentration of anti-TNF
reduced survival of Tregs. Specifically, 5 µg/ml and 25 µg/ml anti-TNF significantly reduced
survival in comparison to untreated control in a concentration-dependent manner. While reduced
survival of Tregs treated with 1 µg/ml anti-TNF did not achieve significance, 2 donors exhibited
a reduction in survival, suggesting that this concentration is the threshold for effect in this assay.
Importantly, the isotype control did not affect cell survival in comparison to untreated cells.
To confirm the role of cell proliferation and apoptosis in overall cell number after 5 days
of stimulation, we analyzed CFSE dilution by flow cytometry and stained with annexin V to
detect phosphatidyl inositol, a marker of apoptosis when exposed on outer leaflet of cell
membranes. In the untreated and isotype controls, annexin V staining was positive in a small
fraction of cells (~20%), indicating few cells undergoing apoptosis (Fig. 11, upper panel).
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However, addition of 1 µg/ml anti-TNF increased annexin V+ cells (~50%) and higher
concentrations resulted in the majority of cells exhibiting an apoptotic phenotype (~80%). Cells
treated with IL-2 did not bind annexin V and increased in size (data not shown). These data
demonstrate that inhibition of TNF increases apoptosis, suggesting a role for TNF in survival of
Tregs in the absence of IL-2.
To test the role of TNF in Treg proliferation in vitro, CFSE dilution was measured by
flow cytometry (Fig. 11, lower panel). About half of all untreated and isotype control-treated
cells proliferated in response to stimulation (~50%) as indicated by dilution of CFSE. In
contrast, fewer cells proliferated in anti-TNF-treated conditions, with almost total abrogation of
cell division in the highest concentration of anti-TNF (~7% cells divided). Together, these data
demonstrate that Tregs fail to proliferate and undergo apoptosis during ex vivo stimulation in the
presence of TNF inhibition.
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Figure 10. Treg survival in response to TNF inhibition. Tregs isolated from peripheral blood
were stimulated by plate-bound anti-CD3 and soluble anti-CD28 in the presence of anti-TNF for
isotype control antibody for 5 days. Cell survival was calculated by comparing cell number of
treated samples to untreated control. Statistical analysis by paired T-test (*p<0.05, ***p<0.001)
with bars representing mean and standard deviation.
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Figure 11. Effect of TNF neutralization on apoptosis and cell proliferation. Tregs were
labeled with CFSE (bottom) prior to stimulation to track proliferation. After 5 days culture with
anti-TNF, cells were stained with Annexin V (top) to detect apoptotic cells. Data representative
of 3 independent experiments with 5 donors total.

Discussion
TNF drives inflammation but also contributes to anti-inflammatory immune responses.
Studies in humans and mice demonstrate TNF mediates autoimmune inflammation, but
inhibition of TNF also results in onset or exacerbation of autoimmunity124. Multiple cells types
can produce TNF and the pleiotropic effects of this cytokine are dependent upon the type of cell
and receptor engaged. Discordant studies of TNF function on immune homeostasis, along with
the identification of TNF expression by cord blood and adult Tregs prompted us to investigate
the function of Treg-derived TNF.
Several studies implicate TNF signaling in the differentiation of Tregs, however we did
not observe any effect of TNF inhibition during cord blood Treg induction. The conditions used
for ex vivo Treg induction in our lab may override any impact of TNF on Foxp3 expression. We
provide exogenous IL-2 to drive Treg differentiation, raising the possibility that IL-2 potently
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induces Tregs and negates any effect of TNF signaling. Furthermore, TNFR2 signaling is
implicated in expansion of Foxp3+ cells, and Tregs induced from cord blood do not express
TNFR2 (data not shown). Therefore, expression of TNFR2 may be important to mouse and
adult human Treg generation. However, we have not directly tested this possibility.
Contradictory studies also report the effects of TNF on suppressive activity of Tregs, however
we did not observe any effect on suppression of naïve T cell proliferation when TNF was
blocked in vitro 127, 129.
Our data demonstrate that Tregs express the membrane form of TNF, which is reported to
selectively signal via TNFR2 and results in growth and survival rather than apoptosis116. To test
the possibility that mTNF promotes survival and proliferation by autocrine signaling, we purified
Tregs from adult peripheral blood and stimulated them in the absence of IL-2 but in the presence
or absence of TNF inhibition. Strikingly, we found that TNF inhibition reduces survival of
Tregs in the absence of IL-2 in vitro and demonstrated an increase in apoptotic phenotype along
with abrogation of proliferation. These results support the hypothesis that mTNF provides
autocrine signals to Tregs to promote survival. However, the impact of TNFR2 in this
phenomenon is correlative. Lack of commercially-available blocking antibodies against TNFR2
necessitate the use of genetic approaches to determine the role of TNFR2 in pro-survival mTNF
signaling. In the future, we aim to knock out or knock down TNFR2 in primary human Tregs in
order to test the involvement of this receptor. In addition, the expression of TNFR2 and mTNF
by mice provides a possible in vivo model system to test TNF signaling in Tregs. While TNFR2
and TNF knockouts exist in mice, the pleiotropic nature of this cytokine necessitates a Treg-
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specific knockout. Future work will aim to knock out TNF or TNFR2 in Foxp3+ T cells in mice
to assess the importance of Treg-derived TNF signaling in vivo.
The presence of the membrane form of TNF on adult Tregs suggests decreased shedding
of soluble TNF, which may account for the differences in the form of TNF expressed by Tregs in
comparison to conventional T cells. The membrane form of TNF must be cleaved by the
metalloprotease TNF alpha converting enzyme (TACE) in order to produce the soluble form115.
Therefore, decreased TACE activity may account for the increased expression of mTNF on
Tregs. TACE forms dimers in cell membranes under resting conditions and is inhibited by the
tissue inhibitor of metalloproteinase 3 (TIMP-3) by direct association with the cytoplasmic
domain of TACE183. Activation of ERK or the p38 MAP kinase pathway results in a shift from
TACE dimers to monomers, relieving inhibition by TIMP-3 and resulting in activation of
TACE183. Tregs exhibit decreased ERK activation after TCR signaling and therefore may
exhibit decreased active TACE and increased TACE dimers associated with TIMP-3184.
Decreased active TACE may account for the increase in the membrane form of TNF, as active
TACE is required to cleave TNF to the soluble form. Inhibition of TACE may prove effective in
controlling inflammation by reducing shedding of soluble TNF. Specifically, modulation of
TIMP-3 activity in macrophages or T cells may be an alternative to TNF inhibition in the
treatment of inflammatory diseases. Future work will aim to modulate shedding of TNF by T
cells through modulation of TACE activation.

CHAPTER SIX
GENERAL DISCUSSION
Our data demonstrate that antigen receptor stimulation of cord blood T cells results in
differentiation of Tregs with distinct phenotype. Cord blood-derived Tregs express a pattern of
chemokine receptors and surface antigens that is distinct from adult peripheral blood Tregs.
Furthermore, production of pro-inflammatory cytokines demonstrates functional differences
between cord blood-derived Tregs and adult tTregs. These data suggest unique roles for fetal
and neonatal Tregs in contrast to adult. Fetal and neonatal immune responses are initiated and
regulated much differently than in adults, raising the possibility that Tregs regulate both
tolerance and inflammation during development and early life and represent an adaptation to the
challenges faced by newborns185.
Distinct chemokine receptor expression by cord blood Tregs suggests that they migrate
differently in response to chemokines. While adult Tregs express high levels of CCR4 and
CCR6 and low levels of CCR7 and CXCR3, we observe the opposite in cord blood-derived
Tregs. In contrast, we observed low CCR4 and CCR6 expression and elevated CCR7 and
CXCR3. These data suggest that cord blood Tregs preferentially traffic to sites of Th1
inflammation and secondary lymphoid tissues rather than taking up residence in skin or other
epithelial tissues186. Furthermore, cord blood-derived Tregs express a profile of surface antigens
that contrasts with adult Tregs. Expression of surface receptors which modulate T cell activation
and tolerance provide further evidence for multifunctionality of cord blood Tregs. In particular,
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CD26 expression distinguishes cord blood from adult Tregs. While this enzyme facilitates a
wide variety of functions, genetic deficiency of one substrate, adenosine deaminase, results in
severe combined immune deficiency (SCID) and death159. Therefore, CD26 function on Tregs
may be crucial to maintenance of immune homeostasis in neonates but not adults. Future work
will seek to determine the role of CD26 activity in neonatal and fetal immune homeostasis.
Despite stable expression of Foxp3 and potent suppressive activity, cord blood Tregs
express multiple pro-inflammatory cytokines. Strikingly, we observe production of IL-8 and
GM-CSF in response to stimulation. IL-8 potently recruits and activates neutrophils to sites of
infection and GM-CSF induces activation and differentiation of monocytes and macrophages174,
178

. IL-8 is considered a prototypic cytokine during infection in neonates, raising the possibility

that cord blood Tregs initiate immune responses in peripheral tissues by recruiting neutrophils to
the site of infection105. GM-CSF production by Th17 cells is linked to neuroinflammation in
MS, however we do not observe IL-17 expression in cord blood Tregs177. Instead, we observe a
group of Foxp3+ cells that express IL-8 and GM-CSF, along with TNF. These data provide
evidence that cord blood Tregs may be able to activate innate immune responses while
suppressing adaptive immunity.
The tolerogenic immune status of infants in dependent upon multiple mechanisms, and
not solely due to Treg-mediated suppression. Th1 responses are harmful to placental
development, and during fetal and neonatal life a bias exists toward Th2 immunity rather than
Th1185. While the precise mechanisms of this phenomenon remain poorly understood, we
demonstrate that the Th1-polarizing cytokine IL-12 reduces proliferation in response to antigen
stimulation, ultimately resulting in cell death. This response may be a means to control
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expansion of Th1 cells and prevent complications during pregnancy, however this hypothesis has
not been tested. In addition, we observe expression of TIM-3 on Tregs, a receptor linked to
inhibition of Th1 immune responses in mice162. These data suggest a role for cord blood Tregs
in maintenance of tolerance via inhibition of Th1 T cell immunity. Furthermore, the induction of
highly inflammatory Th17 cells is reported to develop months after birth139. In agreement, we
observe no difference in Treg generation in Th17-polarizing conditions in vitro, along with a
lack of Th17 generation. The differences in T cell differentiation in cord blood suggest markedly
different adaptive immune responses during pregnancy and early life compared with adult
immunity.
Suppression of T cell proliferation by cord blood Tregs is comparable to adult Tregs,
however unlike tTregs, cord blood-derived Tregs express pro-inflammatory cytokines known to
potently activate innate immunity. Furthermore, chemokine receptor expression suggest cord
blood-derived Tregs migrate to peripheral tissues and lymph nodes to control Th1 inflammation.
Together, these results demonstrate the possibility that multifunctional Tregs from cord blood
suppress adaptive immune responses while regulating innate immunity in peripheral tissues.
Surprisingly, both cord blood and adult Tregs express TNF when stimulated. The proinflammatory functions of TNF are well described, however recently the anti-inflammatory
functions of this pleiotropic cytokine are beginning to be elucidated. Inhibition of TNF is
effective in reducing inflammation in patients with RA and Crohn’s disease, however some
patients display onset or exacerbation of autoimmune inflammation after treatment124. TNF is
also reported to impact suppressive activity of Tregs and induce proliferation of Tregs via
TNFR2127, 134. We did not observe any impact of TNF inhibition on suppressive activity or
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differentiation of Tregs. However, in the absence of IL-2, inhibition of TNF reduced survival of
Tregs and reduced proliferation. Furthermore, increasing concentration of anti-TNF antibody
upregulated apoptosis as indicated by increased phosphatidylserine on the outer leaflet of cell
membranes. We demonstrate that a similar frequency of Tregs and conventional T cells express
TNF, however Foxp3+ T cells preferentially express the membrane form of TNF. TNF is
reported to promote Treg expansion and survival via TNFR2, indicating that autocrine TNF
signaling may be blocked during inhibition of TNF134. Our data support the hypothesis that
Tregs require TNF signaling for survival in the absence of IL-2. In peripheral tissues, where IL2 concentrations are low, Tregs may depend on autocrine TNF to maintain stability and survival.
Therefore, inhibition of TNF in patients may result in inadvertent reduction in Treg frequency in
peripheral tissues. Subsequently, lymphocyte infiltration and proliferation may drive
inflammation observed in some patients due to a paucity of Tregs. In the future, we aim to
investigate the impact of TNF inhibition on Treg homeostasis in the periphery. Furthermore,
modulation of TACE activity may be efficacious in controlling inflammation as an alternative to
TNF inhibition. Future work will investigate the effect of TACE activity modulation in
inflammation.
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